StemCyte International, Ltd. (TPEX:4178)

Market Cap	5.95B
Revenue (ttm)	385.12M
Net Income (ttm)	-187.63M
Shares Out	192.24M
EPS (ttm)	-0.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	290,503
Average Volume	441,495
Open	31.50
Previous Close	32.20
Day's Range	29.95 - 31.90
52-Week Range	20.50 - 44.05
Beta	n/a
RSI	67.58
Earnings Date	Apr 29, 2026

About StemCyte International

StemCyte International, Ltd. operates cord blood cell banks in the United States and Taiwan. It supplies cord blood to medical centers for transplantation in the treatment of blood system diseases; and provides cord blood supply, mononuclear cell supply, and immune cell supply services. The company also develops cord blood to treat COVID-19 syndrome and acute ischemic stroke; and CB201, an immune cell drug. In addition, it offers cord blood storage, immune cell storage, and cord blood cell bank transplant cell services. The company was founded ...

• Industry: Miscellaneous Health And Allied Services, Not Elsewhere Classified
• Founded: 2013
• Country: Cayman Islands
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4178

Financial Performance

In 2024, StemCyte International's revenue was 382.69 million, an increase of 5.49% compared to the previous year's 362.78 million. Losses were -205.66 million, -35.68% less than in 2023.